Need more good news to help pe-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Need more good news to help people

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8 is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology , Biomedical Sciences and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: acce

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":296600242151560,"tweetId":"296600242151560","gmtCreate":1713449685858,"gmtModify":1713449689499,"author":{"id":4111675977273012,"authorId":4111675977273012,"authorIdStr":"4111675977273012","name":"joe3141","avatar":"https://community-static.tradeup.com/news/a947f14f6741fc216021d0b382bd20f8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Need more good news to help people</p></body></html>","htmlText":"<html><head></head><body><p>Need more good news to help people</p></body></html>","text":"Need more good news to help people","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/296600242151560","repostId":2428322019,"repostType":2,"repost":{"id":"2428322019","pubTimestamp":1713378300,"share":"https://www.laohu8.com/m/news/2428322019?lang=&edition=full","pubTime":"2024-04-18 02:25","market":"us","language":"en","title":"BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2428322019","media":"StreetInsider","summary":"Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8 is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.BioMedWire  is a specialized communications platform with a focus on the latest developments in the Biotechnology , Biomedical Sciences  and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers:  acce","content":"<html><body><div>\n<article slug=\"nnwire-2024-4-17-biomednewsbreaks-clene-inc-nasdaq-clnn-announces-study-results-for-cnm-au8-as-multiple-sclerosis-treatment-presented-at-aan-conference\"><p>Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (“AAN”) annual meeting. The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg. for up to three years of treatment, was presented by Dr. Michael Barnett, MBBS, FRACP, FRCP, PhD, from the University of Sydney. The new long-term results from the clinical trial indicate the repair and remyelinating effects of CNM-Au8 treatment in patients, results that further enhance the trial’s findings from the double-blind period of the study. Barnett noted that results from the VISIONARY-MS trial “provide clear impetus” for a definitive phase 3 study. “Observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune system modulation has never been demonstrated in prior multiple sclerosis trials,” said Clene head of medical Dr. Benjamin Greenberg in the press release. “This is a very exciting data set that gives hope to the millions of people who are suffering from this disabling disease.”</p>\n<p>To view the presentation, visit https://ibn.fm/za50w</p>\n<p>To view the full press release, visit https://ibn.fm/05rI9</p>\n<p><strong>About <a href=\"https://laohu8.com/S/CLNN\">Clene Inc</a>.</strong></p>\n<p>Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&amp;D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.</p>\n<p><strong>NOTE TO INVESTORS:</strong> The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN</p>\n<p><strong>About BioMedWire</strong></p><div><div><div></div></div></div>\n<p>BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the <strong>Dynamic Brand Portfolio</strong> @ <strong>IBN</strong> that delivers<strong>:</strong> (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries<strong>;</strong> (2) article and editorial syndication to 5,000+ outlets<strong>;</strong> (3) enhanced press release enhancement to ensure maximum impact<strong>;</strong> (4) social media distribution via IBN to millions of social media followers<strong>;</strong> and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.</p>\n<p>BMW is where breaking news, insightful content and actionable information converge.</p>\n<p><strong>To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)</strong></p>\n<p>For more information, please visit https://www.BioMedWire.com</p>\n<p>Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer</p>\n<p>BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 Office<span>[email protected]</span></p>\n<p>BioMedWire is powered by IBN</p><img height=\"1\" referrerpolicy=\"unsafe-url\" src=\"https://tracking.newsrpm.com/pixel?slug=nnwire-2024-4-17-biomednewsbreaks-clene-inc-nasdaq-clnn-announces-study-results-for-cnm-au8-as-multiple-sclerosis-treatment-presented-at-aan-conference\" width=\"1\"/></article> </div></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 02:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=23079122><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23079122\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PSQ":"纳指反向ETF",".IXIC":"NASDAQ Composite","BK4178":"家庭装饰零售","CLNN":"Clene Inc","QLD":"纳指两倍做多ETF","SQQQ":"纳指三倍做空ETF","BK4585":"ETF&股票定投概念","QQQ":"纳指100ETF","BK4139":"生物科技","CNM":"Core & Main, Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4022":"陆运","BK4232":"货物陆运","R":"瑞德系统","QID":"纳指两倍做空ETF","BK4112":"金融交易所和数据","TQQQ":"纳指三倍做多ETF","AAN":"The Aaron's Company, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=23079122","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2428322019","content_text":"Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (“AAN”) annual meeting. The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg. for up to three years of treatment, was presented by Dr. Michael Barnett, MBBS, FRACP, FRCP, PhD, from the University of Sydney. The new long-term results from the clinical trial indicate the repair and remyelinating effects of CNM-Au8 treatment in patients, results that further enhance the trial’s findings from the double-blind period of the study. Barnett noted that results from the VISIONARY-MS trial “provide clear impetus” for a definitive phase 3 study. “Observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune system modulation has never been demonstrated in prior multiple sclerosis trials,” said Clene head of medical Dr. Benjamin Greenberg in the press release. “This is a very exciting data set that gives hope to the millions of people who are suffering from this disabling disease.”\nTo view the presentation, visit https://ibn.fm/za50w\nTo view the full press release, visit https://ibn.fm/05rI9\nAbout Clene Inc.\nClene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.\nNOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN\nAbout BioMedWire\nBioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.\nBMW is where breaking news, insightful content and actionable information converge.\nTo receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)\nFor more information, please visit https://www.BioMedWire.com\nPlease see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer\nBioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 Office[email protected]\nBioMedWire is powered by IBN","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":28,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}